Clinical Study
Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma
Table 2
Individual characteristics of the 17 patients included in the analysis.
| | Patient code | Type of study | Gender | Age | PS | Stage | Grading | Previous surgery | Previous chemotherapy | Best response | PFS (months) | OS (months) |
| | 1 | P | F | 35 | 2 | Metastatic | G3 | Yes | Yes | PD | 0.9 | 0.9+ | | 2 | P | M | 64 | 0 | Metastatic | G3 | No | Yes | PD | 10.1+ | 10.1+ | | 4 | P | M | 20 | 0 | Metastatic | G3 | Yes | Yes | PR | 1.5+ | 1.5+ | | 5 | P | F | 50 | 1 | Metastatic | G2 | Yes | Yes | PR | 9.0 | 17.7 | | 6 | P | F | 63 | 0 | Metastatic | G2 | Yes | Yes | PD | 10.0 | 33.2 | | 7 | P | F | 67 | 1 | Loc. adv. | G3 | No | Yes | SD | 62.2+ | 62.2+ | | 8 | P | M | 74 | 1 | Metastatic | G2 | Yes | Yes | SD | 5.5 | 45.9+ | | 1001 | R | M | 73 | 1 | Loc. adv. | G3 | Yes | No | SD | 2.7 | 9.6+ | | 1002 | R | M | 70 | 1 | Metastatic | G3 | Yes | Yes | PD |
4.6 | 7.1 | | 1003 | R | F | 66 | 0 | Metastatic | G2 | Yes | Yes | PR | 6.6 | 8.6+ | | 1004 | R | F | 75 | 0 | Metastatic | G3 | Yes | Yes | PR | 3.0 | 16.5 | | 1005 | R | M | 46 | 1 | Metastatic | n.a. | Yes | Yes | SD | 3.5 | 7.6+ | | 1006 | R | F | 61 | 1 | Metastatic | G2 | Yes | Yes | CR | 1.8 | 2.0 | | 1007 | R | F | 62 | n.a. | Metastatic | G3 | Yes | No | PR | 2.0 | 20.8+ | | 1008 | R | M | 71 | n.a. | Loc. adv. | G2 | Yes | No | PD | 3.8 | 7.3 | | 1009 | R | M | 80 | 1 | Loc. adv. | G3 | No | No | SD | 6.0 | 9.9 | | 1010 | R | F | 47 | n.a. | Metastatic | G2 | Yes | No | SD | 1.8 | 18.6 |
|
|
P: prospective; R: retrospective; M: male; F: female; PS: performance status; n.a.: not available; loc. adv.: locally advanced; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; PFS: progression-free survival; OS: overall survival; +: patient censored without event at the last observation.
|
